24/7 Wall Street·22h ago
2 Dirt Cheap Healthcare Stocks to Buy in JulyHealthcare has become Wall Street's bargain bin in 2026, and value hunters are starting to pay attention.
Novo Nordisk A/S(NVO)Earnings, Financials & Key Ratios
NVO•NYSE
$49.64
14.1× P/E·Price updated Jul 7, 2026
AboutNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.Show more
- Revenue$309.06B+6.4%
- EBITDA$149.64B+1.5%
- Net Income$102.43B+1.4%
- EPS (Diluted)23.03+1.8%
- Gross Margin80.98%-4.4%
- EBITDA Margin48.42%-4.6%
- Operating Margin41.3%-6.5%
- Net Margin33.14%-4.7%
- ROE60.7%-24.9%
NVO Price & Volume
Novo Nordisk A/S (NVO) stock price & volume — 10-year historical chart
Loading chart...
Scaling Incretin Production Drives Record Revenue Growth
Investment Thesis • Updated 2026Q1
VerdictPositive
Growth:Accelerating
Profitability:Strong
Financial:Healthy
Cash Flow:Mixed
Primary Risk:Manufacturing capacity and regulatory
Key Thesis Takeaways
- Novo Nordisk is currently executing a massive capital-intensive expansion to meet unprecedented global demand for its GLP-1 metabolic therapies, as evidenced by a 24.0% revenue growth rate in 2026Q1.
- While the company has achieved impressive operational leverage with a 61.6% operating margin, investors should monitor the volatility in free cash flow and the potential risks associated with a 0.79 current ratio.
- The long-term outlook remains supported by a robust 86.0% gross margin, though the sustainability of this trajectory depends on the successful integration of its $220.0B net property, plant, and equipment base.
Verdict Logic
the company demonstrates strong operational performance with 67.1% EPS growth in 2026Q1 and a compelling forward P/E of 2.20, suggesting significant value despite the inherent risks of its capital-intensive manufacturing expansion.
NVO Growth Metrics
Novo Nordisk A/S (NVO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years11.09%
5 Years19.48%
3 Years20.43%
TTM8.13%
Profit CAGR
10 Years11.38%
5 Years19.44%
3 Years22.65%
TTM16.58%
EPS CAGR
10 Years13.04%
5 Years20.65%
3 Years23.52%
TTM16.79%
Return on Capital
10 Years128.26%
5 Years73.17%
3 Years62.34%
Last Year44.36%
NVO Recent Earnings
Novo Nordisk A/S (NVO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 6, 2026Metric
Actual
Est
EPS
$1.04+19.5%
$0.87
Rev
$11.0B+1.5%
$10.9B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$1.00+11.1%
$0.90
Rev
$12.5B+3.1%
$12.1B
Q1 2026
Feb 3, 2026Metric
Actual
Est
EPS
$1.00+11.1%
$0.90
Rev
$12.5B+3.1%
$12.1B
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$1.02+32.5%
$0.77
Rev
$11.8B-4.8%
$12.4B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 6, 2026 | $1.04vs $0.87+19.5% | $11.0Bvs $10.9B+1.5% |
| Q1 2026 | Feb 4, 2026 | $1.00vs $0.90+11.1% | $12.5Bvs $12.1B+3.1% |
| Q1 2026 | Feb 3, 2026 | $1.00vs $0.90+11.1% | $12.5Bvs $12.1B+3.1% |
| Q4 2025 | Nov 5, 2025 | $1.02vs $0.77+32.5% | $11.8Bvs $12.4B-4.8% |
Based on last 12 quarters of dataView full earnings history →
Latest NVO News
Recent stock market news and headlines for Novo Nordisk A/S (NVO)
247 Wallst·1 day ago
The Anti-Magnificent Seven Trade? VGK Is Quietly Creeping Toward Record HighsEuropean stocks are having their loudest year in a decade, and the Vanguard FTSE Europe ETF (NYSEARCA:VGK) is the vehicle most retail investors will consider. VGK trades around $90, up 18% over the past year, while every US finance headline focuses on hyperscaler capex and AI compute. If you want to bet that the next... The Anti-Magnificent Seven Trade? VGK Is Quietly Creeping Toward Record Highs
Fool - Investing News·1 day ago
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?Growth premium vs. value recovery, one trades at 33x forward earnings while the other navigates debt reduction and biosimilar expansion.
Fool - Investing News·1 day ago
Could This Healthcare Stock Help You Build a Real Fortune Over the Next 20 Years?The weight-loss market is crowded, but this company's lead drug candidate has several key advantages.
Seeking Alpha·3 days ago
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business FundamentalsNovo Nordisk (NVO) is rated a BUY as business fundamentals recover faster than the stock price, driven by oral Wegovy's historic U.S. launch. NVO's oral Wegovy is expanding the obesity market, with over 3 million U.S. prescriptions in five months and 80% from GLP-1–naïve patients. Management has raised 2026 guidance, citing stronger-than-expected GLP-1 sales and international growth, with further upward revisions likely.
Peers Comparison
Key metrics vs top competitors for Novo Nordisk A/S (NVO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $49.64 | $220.59B | 14.10 | 6.43% | 33.14% | 60.7% | 3.58% | |
| $1235.56 | $1.17T | 53.84 | 44.7% | 34.98% | 101.17% | — | |
| $42.98 | $103.34B | 11.75 | 5.49% | 16.72% | 10.78% | — | |
| $193.12 | $299.39B | 29.53 | 8.63% | 17.19% | 22.24% | — | |
| $157.03 | $299.63B | 21.84 | 5.97% | 24.14% | 31.42% | — | |
| $133.39 | $2.38B | -39.70 | -2.33% | -6.87% | -4.66% | — |
Compare NVO vs Peers
Novo Nordisk A/S (NVO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when NVO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NVO Frequently Asked Questions
Novo Nordisk A/S (NVO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Novo Nordisk A/S's revenue?
Novo Nordisk A/S (NVO) reported $327.80B in revenue for fiscal year 2025. This represents a 2099% increase from $14.90B in 1996.
How fast is Novo Nordisk A/S growing?
Novo Nordisk A/S (NVO) grew revenue by 6.4% over the past year. This is steady growth.
Is NVO profitable?
Yes, Novo Nordisk A/S (NVO) is profitable, generating $121.96B in net income for fiscal year 2025 (33.1% net margin).
Dividend & Returns
Does NVO pay dividends?
Yes, Novo Nordisk A/S (NVO) pays a dividend with a yield of 3.58%. This makes it attractive for income-focused investors.
What is NVO's return on equity?
Novo Nordisk A/S (NVO) has a return on equity (ROE) of 60.7%. This is excellent, indicating efficient use of shareholder capital.
What is Novo Nordisk A/S's free cash flow?
Novo Nordisk A/S (NVO) generated $31.03B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.